CLINICAL24 Forum: Exploring new biomarkers beyond pTau217 for Alzheimer’s disease
Thursday, December 17 at 16:00 GMT | 17:00 CET | 11:00 EST | 08:00 PST
This expert roundtable will explore the evolving landscape of blood-based biomarkers for Alzheimer’s disease and the opportunities offered by new and complementary approaches. Bringing together leading academic and industry perspectives, the discussion will examine the readiness of blood biomarkers for routine care, the barriers to widespread implementation and the growing demand created by disease-modifying therapies.
The panel will consider the insights provided by pTau217 as an established marker, before exploring the additional dimensions of disease biology that newer biomarkers may reveal. It will examine how emerging biomarkers such as eMTBR-Tau could complement current approaches, support more precise disease staging and contribute to a broader understanding of disease progression.
Attendees will gain practical insight into how multi-biomarker strategies could help identify patients most likely to benefit from therapy, monitor progression over time and complement PET imaging. The conversation will also look ahead to decentralized and at-home collection, wider access for rural and underserved populations, and the challenges of scaling screening programs globally.
Certificate of Attendance
All attendees who join the live forum will automatically receive a certificate of attendance, including a summary of key learning outcomes, to support their continuing professional development.
If you watch the on-demand recording, you may request a certificate of attendance by emailing editor@selectscience.net.
Forum Details
• Cost: Free to attend
• Location: Online
• Duration: 60 minutes
• Format: Discussion format
Can't Attend Live?
Register to receive access to the recording after the event, allowing you to catch up on the discussion and revisit key insights at your convenience.
About CLINICAL24
CLINICAL24 is a global initiative dedicated to exploring the challenges facing modern clinical laboratories and highlighting the technologies, expertise, and collaborative approaches helping to improve patient care worldwide.
Speakers
What will this webinar cover?
- Assess the current readiness of blood-based biomarkers for routine Alzheimer’s disease testing and the barriers to wider clinical adoption.
- Explain the strengths and limitations of pTau217 and how emerging biomarkers, including eMTBR-Tau, could provide complementary biological insight.
- Explore how multi-biomarker approaches could support disease staging, treatment selection, progression monitoring and the use of PET imaging.
- Evaluate the opportunities and practical challenges associated with decentralized and at-home testing, particularly for rural and underserved populations.
- Consider how blood biomarkers, imaging, clinical assessment and AI could combine to shape more accessible and personalized diagnostic pathways by 2030.